TY - JOUR T1 - Clinical consequences of using the new cardiovascular risk tables SCORE OP in patients aged over 65 years JO - Medicina Clínica (English Edition) T2 - AU - Brotons,Carlos AU - Moral,Irene AU - Fernández,Diana AU - Cuixart,Lluis AU - Muñoz,Alex AU - Soteras,Anna AU - Puig,Mireia AU - Joaniquet,Xavier AU - Casasa,Albert SN - 23870206 M3 - 10.1016/j.medcle.2016.11.026 DO - 10.1016/j.medcle.2016.11.026 UR - https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-clinical-consequences-using-new-cardiovascular-S2387020616306970 AB - Background and objectiveEstimating cardiovascular risk with SCORE is not recommended in persons over 65 years. SCORE investigators have recently published specific tables for older people (SCORE Older Persons [SCORE OP]). The aim of this study is to assess the impact of using SCORE OP tables on a Spanish population aged over 64 years, and compare it with the use of SCORE in patients aged 65–69 years. Patients and methodCross-sectional study carried out in 2 urban primary health care centres. Individuals between 65 and 85 years old without diabetes or established cardiovascular diseases were included. Cardiovascular risk using SCORE and the new SCORE OP tables for low risk countries was calculated. ResultsCardiovascular risk was estimated in 3425 patients. Mean values of the original SCORE and SCORE OP were 4.08 and 3.83, respectively in the group of patients aged 65–69 years old (n=974, 22.44%) (p<.001). The percentage of patients at high or very high risk was 25.46% and 22.90% with the original SCORE and the SCORE OP, respectively (p<.001). Using the original SCORE, 16.43% of the total patients should potentially be treated with lipid lowering drugs, while using the SCORE OP, 13.45% of the patients aged 65–69 years should potentially be treated. Using SCORE OP in patients older than 69 years, 61.49% patients should potentially be treated with lipid lowering drugs. ConclusionsSCORE OP identifies fewer patients at high or very high risk than the original SCORE, therefore, its utilization would imply treating fewer patients of this age with lipid lowering drugs. ER -